Theranos

Good-Bye to Theranos

Blood-testing firm Theranos is to shutter, the Wall Street Journal reports.

A federal grand jury has indicted Elizabeth Holmes and Ramesh Balwani for alleged wire fraud in conjunction with their activities at Theranos.

Still Going for Small

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

The US Securities and Exchange Commission charged Elizabeth Holmes, the founder and CEO of Theranos, with fraud.

The Wall Street Journal reports that the erstwhile partners have reached a settlement of more than $25 million.

Asking for the Data

Biotech investors are learning from their mistakes following the Theranos fiasco, according to Wired.

Theranos Settles

The embattled firm has reached deals with both the Centers for Medicare & Medicaid Services and Arizona.

Elizabeth Holmes, the founder of Theranos, owes the firm millions, the Wall Street Journal reports.

'Repeated Violations'

A federal inspection report obtained by the Wall Street Journal describes deficiencies at Theranos' Arizona lab.

Second Failure

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.

Pages

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.